A phase i study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination

Prostate

Volumn 75, Issue 14, 2015, Pages 1518-1525

  Paller, Channing J ^a   Rudek, Michelle A ^a   Zhou, Xian C ^a   Wagner, William D ^b   Hudson, Tamaro S ^c   Anders, Nicole ^a   Hammers, Hans J ^a   Dowling, Donna ^a   King, Serina ^a   Antonarakis, Emmanuel S ^a   Drake, Charles G ^a   Eisenberger, Mario A ^a   Denmeade, Samuel R ^a   Rosner, Gary L ^a   Carducci, Michael A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c HOWARD UNIVERSITY CANCER CENTER   (United States)

Author keywords

complementary therapy; muscadine grape skin; prostate cancer; PSADT; rising PSA

Indexed keywords

ANTINEOPLASTIC AGENT; GLUCOSE; MPX; UNCLASSIFIED DRUG; PLANT EXTRACT;

ABDOMINAL DISTENSION; ABNORMAL FECES; ADULT; AGED; ARTICLE; BACKACHE; BIOCHEMICALLY RECURRENT PROSTATE CANCER; BRONCHITIS; CLINICAL ARTICLE; COHORT ANALYSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERUCTATION; FATIGUE; FLATULENCE; HUMAN; LEG PAIN; LOW DRUG DOSE; MALE; MYASTHENIA GRAVIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PTOSIS; UNSPECIFIED SIDE EFFECT; CHEMICALLY INDUCED; CLINICAL TRIAL; FOLLOW UP; GASTROINTESTINAL DISEASES; ISOLATION AND PURIFICATION; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; PROSTATIC NEOPLASMS; TUMOR RECURRENCE; VITIS;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; GASTROINTESTINAL DISEASES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PLANT EXTRACTS; PROSTATIC NEOPLASMS; VITIS;

EID: 84939207788     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.23024     Document Type: Article

References (39)

1. Siegel RL, Miller KD, Jemal A,. Cancer statistics, 2015. CA Cancer J Clin 2015; 65 (1): 5-29.
2. Paller CJ, Antonarakis ES, Eisenberger MA, Carducci MA,. Management of patients with biochemical recurrence after local therapy for prostate cancer. Hematol Oncol Clin North Am 2013; 27 (6): 1205-1219.
3. Uchio EM, Aslan M, Wells CK, Calderone J, Concato J,. Impact of biochemical recurrence in prostate cancer among US veterans. Arch Intern Med 2010; 170 (15): 1390-1395.
4. Schweizer MT, Zhou XC, Wang H, Yang T, Shaukat F, Partin AW, Eisenberger MA, Antonarakis ES,. Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy. Ann Oncol 2013; 24 (11): 2881-2886.
5. Thompson CA, Shanafelt TD, Loprinzi CL,. Andropause: Symptom management for prostate cancer patients treated with hormonal ablation. Oncologist 2003; 8 (5): 474-487.
6. Paller CJ, Antonarakis ES,. Management of biochemically recurrent prostate cancer after local therapy: Evolving standards of care and new directions. Clin Adv Hematol Oncol 2013; 11 (1): 14-23.
7. Hudson TS, Hartle DK, Hursting SD, Nunez NP, Wang TT, Young HA, Arany P, Green JE,. Inhibition of prostate cancer growth by muscadine grape skin extract and resveratrol through distinct mechanisms. Cancer Res 2007; 67 (17): 8396-8405.
8. Yi W, Fischer J, Akoh CC,. Study of anticancer activities of muscadine grape phenolics in vitro. J Agric Food Chem 2005; 53 (22): 8804-8812.
9. Balan V, Wang Y, Nangia-Makker P, Kho D, Bajaj M, Smith D, Heilbrun L, Raz A, Heath E,. Galectin-3: A possible complementary marker to the PSA blood test. Oncotarget 2013; 4 (4): 542-549.
10. Xia EQ, Deng GF, Guo YJ, Li HB,. Biological activities of polyphenols from grapes. Int J Mol Sci 2010; 11 (2): 622-646.
11. Seeram NP, Aronson WJ, Zhang Y, Henning SM, Moro A, Lee RP, Sartippour M, Harris DM, Rettig M, Suchard MA, Pantuck AJ, Belldegrun A, Heber D,. Pomegranate ellagitannin-derived metabolites inhibit prostate cancer growth and localize to the mouse prostate gland. J Agric Food Chem 2007; 55 (19): 7732-7737.
12. Adams LS, Seeram NP, Aggarwal BB, Takada Y, Sand D, Heber D,. Pomegranate juice, total pomegranate ellagitannins, and punicalagin suppress inflammatory cell signaling in colon cancer cells. J Agric Food Chem 2006; 54 (3): 980-985.
13. Xing N, Chen Y, Mitchell SH, Young CY,. Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis 2001; 22 (3): 409-414.
14. Nair HK, Rao KV, Aalinkeel R, Mahajan S, Chawda R, Schwartz SA,. Inhibition of prostate cancer cell colony formation by the flavonoid quercetin correlates with modulation of specific regulatory genes. Clin Diagn Lab Immunol 2004; 11 (1): 63-69.
15. Weber G, Shen F, Prajda N, Yang H, Li W, Yeh A, Csokay B, Olah E, Look KY,. Regulation of the signal transduction program by drugs. Adv Enzyme Regul 1997; 37: 35-55.
16. Plaumann B, Fritsche M, Rimpler H, Brandner G, Hess RD,. Flavonoids activate wild-type p53. Oncogene 1996; 13 (8): 1605-1614.
17. Mouria M, Gukovskaya AS, Jung Y, Buechler P, Hines OJ, Reber HA, Pandol SJ,. Food-derived polyphenols inhibit pancreatic cancer growth through mitochondrial cytochrome C release and apoptosis. Int J Cancer 2002; 98 (5): 761-769.
18. Barber NJ, Zhang X, Zhu G, Pramanik R, Barber JA, Martin FL, Morris JD, Muir GH,. Lycopene inhibits DNA synthesis in primary prostate epithelial cells in vitro and its administration is associated with a reduced prostate-specific antigen velocity in a phase II clinical study. Prostate Cancer Prostatic Dis 2006; 9 (4): 407-413.
19. Grainger EM, Schwartz SJ, Wang S, Unlu NZ, Boileau TW, Ferketich AK, Monk JP, Gong MC, Bahnson RR, DeGroff VL, Clinton SK,. A combination of tomato and soy products for men with recurring prostate cancer and rising prostate specific antigen. Nutr Cancer 2008; 60 (2): 145-154.
20. Paller CJ, Ye X, Wozniak PJ, Gillespie BK, Sieber PR, Greengold RH, Stockton BR, Hertzman BL, Efros MD, Roper RP, Liker HR, Carducci MA,. A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer. Prostate Cancer Prostatic Dis 2013; 16 (1): 50-55.
21. Thomas R, Williams M, Sharma H, Chaudry A, Bellamy P,. A double-blind, placebo-controlled randomised trial evaluating the effect of a polyphenol-rich whole food supplement on PSA progression in men with prostate cancer-the U.K. NCRN Pomi-T study. Prostate Cancer Prostatic Dis 2014; 17 (2): 180-186.
22. Antonarakis ES, Zahurak ML, Lin J, Keizman D, Carducci MA, Eisenberger MA,. Changes in PSA kinetics predict metastasis- free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: Combined analysis of 4 phase II trials. Cancer 2012; 118 (6): 1533-1542.
23. Suzman DL, Zhou XC, Zahurak ML, Lin J, Antonarakis ES,. Change in PSA velocity is a predictor of overall survival in men with biochemically-recurrent prostate cancer treated with nonhormonal agents: Combined analysis of four phase-2 trials. Prostate Cancer Prostatic Dis 2015; 18 (1): 49-55.
24. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M,. Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26 (7): 1148-1159.
25. Carpentier A, Brandes A, Kesari S, Sepulveda J, Wheeler H, Chinot O, Cher L, Steinbach J, Specenier P, Cleverly A, Tomlin I, Desaiah D, Lahn M, Wick W,. Safety interim data from a 3-arm phase 2 study evaluating safety and pharmacokinetics of the oral transforming growth factor-beta receptor I kinase inhibitor LY 2157 299 monohydrate in patients with glioblastoma at first progression. J Clin Oncol 2013; 31 (suppl; abstr 2061).
26. Arlen PM, Bianco F, Dahut WL, D'Amico A, Figg WD, Freedland SJ, Gulley JL, Kantoff PW, Kattan MW, Lee A, Regan MM, Sartor O,. Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol 2008; 179 (6): 2181-2185.
27. Onar A, Kocak M, Boyett JM,. Continual reassessment method vs. traditional empirically based design: Modifications motivated by Phase I trials in pediatric oncology by the Pediatric Brain Tumor Consortium. J Biopharm Stat 2009; 19 (3): 437-455.
28. Garrett-Mayer E., The continual reassessment method for dose-finding studies: A tutorial. Clin Trials 2006; 3 (1): 57-71.
29. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW,. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294 (4): 433-439.
30. Velicer CM, Ulrich CM,. Vitamin and mineral supplement use among US adults after cancer diagnosis: A systematic review. J Clin Oncol 2008; 26 (4): 665-673.
31. Patterson RE, Neuhouser ML, Hedderson MM, Schwartz SM, Standish LJ, Bowen DJ,. Changes in diet, physical activity, and supplement use among adults diagnosed with cancer. J Am Diet Assoc 2003; 103 (3): 323-328.
32. https://www.ftc.gov/news-events/press-releases/2013/01/ftc-commissioners-uphold-trial-judge-decision-pom-wonderful-llc. Accessed March 21, 2015.
33. Klein EA, Thompson IM, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL, Baker LH,. Vitamin E and the risk of prostate cancer: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011; 306 (14): 1549-1556.
34. Keating NL, O'Malley AJ, Smith MR,. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24 (27): 4448-4456.
35. Cai X, Fang Z, Dou J, Yu A, Zhai G,. Bioavailability of quercetin: Problems and promises. Curr Med Chem 2013; 20 (20): 2572-2582.
36. Lipinska L, Klewicka E, Sojka M,. The structure, occurrence and biological activity of ellagitannins: A general review. Acta Sci Pol Technol Aliment 2014; 13 (3): 289-299.
37. Walle T., Bioavailability of resveratrol. Ann NY Acad Sci 2011; 1215: 9-15.
38. Paller CJ, Olatoye D, Xie S, Zhou X, Denmeade SR, Eisenberger MA, Antonarakis ES, Carducci MA, Rosner GL,. The effect of the frequency and duration of PSA measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer. Prostate Cancer Prostatic Dis 2014; 17 (1): 28-33.
39. Mikhak B, Hunter DJ, Spiegelman D, Platz EA, Wu K, Erdman JW Jr., Giovannucci FES,. Manganese superoxide dismutase (MnSOD) gene polymorphism, interactions with carotenoid levels and prostate cancer risk. Carcinogenesis, 2008. 29 (12): 2335-2340.